Sequence Variation in Vitamin K Epoxide Reductase Gene Is Associated With Survival and Progressive Coronary Calcification in Chronic Kidney Disease

Objective—Sequence variations in the gene(s) encoding vitamin K epoxide reductase complex subunit 1 (VKORC1), the enzyme target of warfarin, have been associated with increased cardiovascular disease in the general population. Coronary artery calcification (CAC) is a prevalent form of cardiovascular disease in chronic kidney disease. We tested the hypothesis that the VKORC1 rs8050894 CC genotype would be associated with mortality and progression of CAC ⩽4 years. Approach and Results—This study is an observational, prospective study of 167 individuals with stages 3 to 5 chronic kidney disease. Survival ⩽4 years was assessed in all participants, and CAC progression was measured in a subset of 86 patients. Participants with the CG/GG genotype of VKORC1 had higher baseline CAC scores (median score, 112 versus 299; P=0.036). Of those 86 patients who had a 4-year CAC score, those with the CG/GG genotype had an increased risk of progressive CAC (adjusted for age, diabetes mellitus, estimated glomerular filtration rate, and hypertension) compared with those with the CC genotype. Four-year mortality risk was 4 times higher for individuals with the CG/GG genotypes compared with individuals with the CC genotype (odds ratio, 3.8; 95% confidence interval, 1.2–12.5; P=0.02), adjusted for age, sex, diabetes mellitus, estimated glomerular filtration rate, baseline CAC, and hypertension. Conclusions—Patients with the CG/GG genotype of VKORC1 had a higher risk of CAC progression and a poorer survival. These data provide new perspectives on the potential extrahepatic role of VKORC1 in individuals with chronic kidney disease.

[1]  V. Lattard,et al.  VKORC1L1, an Enzyme Rescuing the Vitamin K 2,3-Epoxide Reductase Activity in Some Extrahepatic Tissues during Anticoagulation Therapy* , 2013, The Journal of Biological Chemistry.

[2]  Xueyan Fu,et al.  Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. , 2013, Kidney international.

[3]  W. Aronow,et al.  Association of Warfarin Use With Valvular and Vascular Calcification: A Review , 2011, Clinical cardiology.

[4]  P. Schreiner,et al.  An Association Between Clotting Factor VII and Carotid Intima-Media Thickness: The CARDIA Study , 2010, Stroke.

[5]  S. Booth,et al.  Vitamins K and D status in stages 3-5 chronic kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[6]  K. Chinnaiyan,et al.  Annual progression of coronary calcification in trials of preventive therapies: a systematic review. , 2009, Archives of internal medicine.

[7]  M. Cancela,et al.  Gla-rich protein is a novel vitamin K-dependent protein present in serum that accumulates at sites of pathological calcifications. , 2009, The American journal of pathology.

[8]  W. Aronow,et al.  Warfarin use and the risk of valvular calcification , 2009, Journal of thrombosis and haemostasis : JTH.

[9]  D. Torigian,et al.  Correlates of Valvular Ossification in Patients with Aortic Valve Stenosis , 2009, Clinical and translational science.

[10]  T. Villines,et al.  Does Prolonged Warfarin Exposure Potentiate Coronary Calcification in Humans? Results of the Warfarin and Coronary Calcification Study , 2009, Calcified Tissue International.

[11]  K. Seung,et al.  Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study. , 2009, American heart journal.

[12]  S. Booth,et al.  Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status. , 2009, Journal of nutritional science and vitaminology.

[13]  R. D'Agostino,et al.  Genetic and non-genetic correlates of vitamins K and D , 2009, European Journal of Clinical Nutrition.

[14]  A. Mahnken,et al.  Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification , 2009, Thrombosis and Haemostasis.

[15]  A. R. Morton,et al.  Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Tom Greene,et al.  Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)) , 2008 .

[17]  M. Rieder,et al.  An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients , 2008, Thrombosis and Haemostasis.

[18]  A. Hofman,et al.  Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification: The Rotterdam Study , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[19]  L. Schurgers,et al.  Post‐translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  L. Hindorff,et al.  Common VKORC1 variants are not associated with arterial or venous thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[21]  P. Reitsma.  VKORC1 gene variation and venous thrombosis: ‘another one bites the dust’? , 2007, Journal of thrombosis and haemostasis : JTH.

[22]  E. Oger,et al.  Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study , 2007, Journal of thrombosis and haemostasis : JTH.

[23]  J. Oldenburg,et al.  Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans , 2007, Thrombosis and Haemostasis.

[24]  A. Peixoto,et al.  Effects of Warfarin on Blood Pressure in Men With Diabetes and Hypertension—A Longitudinal Study , 2007, Journal of clinical hypertension.

[25]  M. Rieder,et al.  Coagulation factor VII gene haplotypes, obesity‐related traits, and cardiovascular risk in young women , 2007, Journal of thrombosis and haemostasis : JTH.

[26]  C. Shanahan,et al.  Molecular mechanisms mediating vascular calcification: Role of matrix Gla protein (Review Article) , 2006, Nephrology.

[27]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[28]  Yibo Wang,et al.  VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection) , 2006, Circulation.

[29]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[30]  H. Halkin,et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.

[31]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[32]  K. Borch-Johnsen,et al.  Inflammation, thrombosis and atherosclerosis: results of the Glostrup study , 2003, Journal of thrombosis and haemostasis : JTH.

[33]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[34]  G. Assmann,et al.  Coagulation factor VII and the risk of coronary heart disease in healthy men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[35]  V. Fuster,et al.  Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. , 1996, Circulation.

[36]  N. Ossei-Gerning,et al.  Association of Factor VII:C Levels with Environmental and Genetic Factors in Patients with Ischaemic Heart Disease and Coronary Atheroma Characterised by Angiography , 1996, Thrombosis and Haemostasis.

[37]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[38]  P. Reitsma,et al.  VKORC1 and the vitamin K cycle. , 2008, Vitamins and hormones.

[39]  M. Shearer,et al.  Ethnic differences in osteocalcin γ-carboxylation, plasma phylloquinone (vitamin K1) and apolipoprotein E genotype , 2005, European Journal of Clinical Nutrition.

[40]  N. Chen,et al.  Vascular calcification in chronic kidney disease. , 2004, Seminars in nephrology.

[41]  J. Sadowski,et al.  Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. , 1997, Methods in enzymology.